Edwards Lifesciences (NYSE:EW – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday, Wall Street Zen reports.
EW has been the topic of several other research reports. BTIG Research reissued a “buy” rating and set a $110.00 price objective on shares of Edwards Lifesciences in a research note on Friday, September 11th. UBS Group began coverage on shares of Edwards Lifesciences in a research note on Tuesday, July 28th. They issued a “buy” rating and a $110.00 target price for the company. Citigroup increased their target price on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Leerink Partners raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $87.00 to $101.00 in a research report on Friday, July 24th. Finally, Truist Financial lifted their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a research report on Thursday, July 16th. Seventeen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $100.27.
Get Our Latest Analysis on Edwards Lifesciences
Edwards Lifesciences Stock Up 0.1%
Edwards Lifesciences (NYSE:EW – Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. During the same quarter in the prior year, the firm posted $0.67 earnings per share. The company’s quarterly revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Research analysts predict that Edwards Lifesciences will post 3 EPS for the current year.
Insider Activity at Edwards Lifesciences
In other Edwards Lifesciences news, VP Annette Brüls sold 2,644 shares of Edwards Lifesciences stock in a transaction on Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the sale, the vice president directly owned 17,984 shares in the company, valued at approximately $1,618,200.32. The trade was a 12.82% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Andrew M. Dahl sold 544 shares of the business’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the sale, the senior vice president directly owned 14,868 shares in the company, valued at $1,353,880.08. This trade represents a 3.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 5,664 shares of company stock valued at $511,918. Corporate insiders own 0.31% of the company’s stock.
Institutional Trading of Edwards Lifesciences
A number of hedge funds and other institutional investors have recently modified their holdings of EW. BlackRock Inc. bought a new position in Edwards Lifesciences in the second quarter valued at approximately $5,318,092,000. Bank of New York Mellon Corp acquired a new position in shares of Edwards Lifesciences during the 2nd quarter worth approximately $1,274,082,000. Norges Bank bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth approximately $803,686,000. Bank of America Corp DE bought a new stake in shares of Edwards Lifesciences during the 2nd quarter worth approximately $605,397,000. Finally, Deutsche Bank AG acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $516,552,000. Institutional investors and hedge funds own 79.46% of the company’s stock.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.
The company’s portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.
Read More
- Five stocks we like better than Edwards Lifesciences
- Data Centers Got the AI Hype—But Office REITs May Get the Rent Hikes
- 2 Cybersecurity Stocks Breaking Out as AI Continues to Be a Tailwind
- 3 More AI Infrastructure Plays Beyond the Big Names
- CAVA Stock Slips: Sector Fear or Valuation Reality?
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
